---
title: "Varegacestat (AL102) in Desmoid tumors: AL102-502"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: AL102-502. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 14 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence/al102-502"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: AL102-502

<a id="heading-3.1.5"></a>

## 3.1.5 AL102-502

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Effect of a single varegacestat dose on cardiac repolarization

> “A Phase 1, Randomized, Single-Dose, Positive- and Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effects of Varegacestat on Cardiac Repolarization in Healthy Participants”
> “This clinical study is designed to study the effect of a single dose of varegacestat on cardiac repolarization in healthy adult participants.”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Registry status, dates, and site

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “AL102-502” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-02-24” |
| Primary completion (actual) | “2025-04-08” |
| Study completion (actual) | “2025-05-06” |
| First posted | “2025-03-03” |
| Last update posted | “2025-09-24” |
| Site | “Celerion”; “Tempe” |

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Randomized, placebo- and moxifloxacin-controlled, three-way crossover

> “This is a double-blind (with respect to varegacestat and placebo only), single-dose, randomized, placebo- and positive- controlled, 3-way crossover study.”
> “In each period, cardiodynamic ECGs will be collected predose and for 24 hours postdose.”
> “There will be a washout of at least 14 days between doses. Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="topic-3.1.5.3-2"></a>

#### Registry design fields

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Intervention model | “Crossover Assignment” |
| Masking | “This is a double-blind study (with respect to varegacestat and placebo only; moxifloxacin will be open label).” |
| Primary purpose | “Other” |
| Keyword | “thorough-QT” |

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Healthy adults aged 18 to 55 years

> “Healthy, adult, male or female (of non childbearing potential), 18 to 55 years of age, inclusive, at the screening visit.”
> “Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, and vital signs, as deemed by the PI or designee”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="topic-3.1.5.4-2"></a>

#### Exclusion criteria

> “History of any illness that, in the opinion of the PI or designee, might confound the results of the study or pose an additional risk to the participant by their participation in the study.”
> “Have taken an investigational drug or participated in a clinical trial evaluating an investigational drug or device within 30 days (or 5 half-lives) prior to the study drug dose, whichever is longer.”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Single doses of varegacestat, placebo, and moxifloxacin 400 mg

> “On Day 1 of each period, participants will receive one of 3 treatments: a single dose of varegacestat (Treatment A), a single dose of varegacestat matching placebo (Treatment B), or a single dose of moxifloxacin (Treatment C).”
> “Single oral dose of varegacestat”
> “Moxifloxacin 400 mg”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Placebo-corrected QTc Change as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Primary endpoint: placebo-corrected QTc change and plasma concentrations

> “Placebo-corrected change from baseline QTc and varegacestat and its metabolite, AL102 MTB, plasma concentrations”
> “PK samples will be collected predose and up to 168 hours post-dose for assessments of varegacestat and AL102 MTB, and up to 24 hours post-dose for assessment of moxifloxacin.”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="topic-3.1.5.6.1-2"></a>

##### Delayed cardiac repolarization and torsade de pointes

> “The QT interval represents the duration of ventricular depolarization and subsequent repolarization, and is measured from the beginning of the QRS complex to the end of the T wave.”
> “A delay in cardiac repolarization creates an electrophysiological environment that favors the development of cardiac arrhythmias, most clearly torsade de pointes (TdP), but possibly other ventricular tachyarrhythmias as well.”

Source: [FDA guidance, E14 clinical evaluation of QT/QTc interval prolongation (2005)](https://www.fda.gov/media/71372/download)

<a id="topic-3.1.5.6.1-3"></a>

##### Purpose of a thorough QT/QTc study and the threshold of regulatory concern

> “The “thorough QT/QTc study” is intended to determine whether the drug has a threshold pharmacologic effect on cardiac repolarization, as detected by QT/QTc prolongation.”
> “The threshold level of regulatory concern, discussed further below, is around 5 ms as evidenced by an upper bound of the 95% confidence interval around the mean effect on QTc of 10 ms.”
> “Based on similar considerations, a negative “thorough QT/QTc study” is one in which the upper bound of the 95% one-sided confidence interval for the largest time-matched mean effect of the drug on the QTc interval excludes 10 ms.”

Source: [FDA guidance, E14 clinical evaluation of QT/QTc interval prolongation (2005)](https://www.fda.gov/media/71372/download)

<a id="topic-3.1.5.6.1-4"></a>

##### Positive control to establish assay sensitivity

> “The confidence in the ability of the study to detect QT/QTc prolongation can be greatly enhanced by the use of a concurrent positive control group (pharmacological or nonpharmacological) to establish assay sensitivity.”

Source: [FDA guidance, E14 clinical evaluation of QT/QTc interval prolongation (2005)](https://www.fda.gov/media/71372/download)

<a id="topic-3.1.5.6.1-5"></a>

##### Secondary endpoints: ECG parameters, pharmacokinetics, safety, and assay sensitivity

> “Change from baseline, placebo-corrected, and categorical outliers of the ECG parameter QTcF from a single oral dose of varegacestat.”
> “Change from baseline, placebo-corrected, and categorical outliers of the ECG parameter HR from a single oral dose of varegacestat.”
> “Safety and tolerability of a single oral dose of varegacestat by incidences of treatment-emergent adverse events.”
> “Assay sensitivity of the study to detect a small QTc effect using moxifloxacin as a positive control.”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Actual enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (actual) | “32” |

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary

- AL102-502 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-04-08, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of varegacestat on the QTc interval is unknown from public sources.
- The study gave a single oral dose of varegacestat to 32 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. The registry record does not state the dose. In the phase 1 study of BMS-986115, the median accumulation ratio after once-daily dosing at 1.2 mg was 3.66, so exposure after a single dose is lower than exposure after 15 days of once-daily dosing.
- Moxifloxacin, the positive control, was given open label, and blinding applied to varegacestat and placebo only.

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264); [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
